|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
Central and Peripheral Effects of Insulin/IGF-1 Signaling in Aging and Cancer: Antidiabetic Drugs as Geroprotectors and Anticarcinogens
aN.N. Petrov Research Institute of Oncology, St. Petersburg 197758, Russia bCenter for Demographic Studies, Duke University, Durham, North Carolina 27708, USA
Address for correspondence: Vladimir N. Anisimov, N.N. Petrov Research Institute of Oncology, St. Petersburg 197758, Russia. Voice: +7(812)596-8607; fax: +7(812)596-8947. aging{at}mail.ru
Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors both in aging and in the development of cancer. Insulin/insulin-like growth factor 1 (IGF-1) signaling molecules linked to longevity include DAF-2 and insulin receptor (InR) and their homologues in mammals and to inactivation of the corresponding genes followed by increased life span in nematodes, fruit flies, and mice. It is possible that the life-prolonging effect of caloric restriction are due to decreasing IGF-1 levels. A search of pharmacological modulators of life span-extending mutations in the insulin/IGF-1 signaling pathway and mimetics of effects of caloric restriction could be a direction in the regulation of longevity. Some literature and our own observations suggest that antidiabetic drugs could be promising candidates for both life span extension and prevention of cancer.
Key Words: insulin • IGF-1 • antidiabetic drugs • life span • cancer
|
 |
 |
